Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17491970 | 1.00 | GPR34 (0.44) | GPR34SMN1; SMN2PPARGVNN1MEN1 | |
| SCHEMBL17492145 | 0.89 | MMP2 (0.44) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL17492142 | 0.89 | MMP2 (0.44) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL6221169 | 0.87 | MTNR1A (0.46) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL17491905 | 0.87 | MTNR1A (0.46) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL17491904 | 0.87 | MTNR1A (0.46) | MEN1ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL17492043 | 0.85 | MTNR1A (0.50) | ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL17492041 | 0.85 | MTNR1A (0.50) | ALDH1A1LMNAKMT2AGAA | |
| SCHEMBL16820532 | 0.84 | MDM4 (0.43) | MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL16820533 | 0.84 | MDM4 (0.43) | MEN1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106459147-B | Serine derivatives as ghrelin receptor agonists | 拉夸里亚创药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| EP-3131916-B1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-9873695-B2 | Serine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3131916-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc (JP) | 2017-02-22 | — | — | EP | disclosed |
| WO-2016021191-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | GPR34 139/4885SMN1; SMN2 1251/4885PPARG 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.